Abstract:What's new? Resistance to targeted and immune therapies limits the benefits of current treatments in melanoma. This study provides evidence for a new combined approach in targeting BRAF inhibitor‐resistant melanoma. Pharmacological inhibition of the resistance‐inducing Rho/MRTF pathway using CCG‐257081 enhanced the response to PD1/PDL1 blockade in vivo. Moreover, anti‐PD1/CCG‐257081 co‐treatment increased infiltration of CD8+ T cells and B cells into the tumor microenvironment and reduced tumor‐associated macrophage infiltration. CCG‐257081 emerges as a potential new anti‐resistance agent that can improve the response to immune checkpoint inhibitors in advanced melanoma. Metastatic cutaneous melanoma is a fatal skin cancer. Resistance to targeted and immune therapies limits the benefits of current treatments. Identifying and adding anti‐resistance agents to current treatment protocols can potentially improve clinical responses. Myocardin‐related transcription factor (MRTF) is a transcriptional coactivator whose activity is indirectly regulated by actin and the Rho family of GTPases. We previously demonstrated that development of BRAF inhibitor (BRAFi) resistance frequently activates the Rho/MRTF pathway in human and mouse BRAFV600E melanomas. In clinical trials, pretreatment with BRAFi reduces the benefit of immune therapies. We aimed to test the efficacy of concurrent treatment with our MRTF pathway inhibitor CCG‐257081 and anti‐PD1 in vivo and to examine its effects on the melanoma immune microenvironment. Because MRTF pathway activation upregulates the expression of immune checkpoint inhibitor genes/proteins, we asked whether CCG‐257081 can improve the response to immune checkpoint blockade. CCG‐257081 reduced the expression of PDL1 in BRAFi‐resistant melanoma cells and decreased surface PDL1 levels on both BRAFi‐sensitive and ‐resistant melanoma cells. Using our recently described murine vemurafenib‐resistant melanoma model, we found that CCG‐257081, in combination with anti‐PD1 immune therapy, reduced tumor growth and increased survival. Moreover, anti‐PD1/CCG‐257081 co‐treatment increased infiltration of CD8+ T cells and B cells into the tumor microenvironment and reduced tumor‐associated macrophages. Here, we propose CCG‐257081 as an anti‐resistance and immune therapy‐enhancing anti‐melanoma agent.

Analogs of Cyclic Peptide Mortiamide‐D From Marine Fungi Have Improved Membrane Permeability and Kill Drug‐Resistant Melanoma Cells

Cyclic tachyplesin I kills proliferative, non-proliferative and drug-resistant melanoma cells without inducing resistance

Bis-Cinnamamide Derivatives as APE/Ref-1 Inhibitors for the Treatment of Human Melanoma

Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues

Liposomal C6 Ceramide Activates Protein Phosphatase 1 to Inhibit Melanoma Cells

Mitochondrial Voltage-Dependent Anion Channel 1–Hexokinase-II Complex-Targeted Strategy for Melanoma Inhibition Using Designed Multiblock Peptide Amphiphiles

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA

Selective Inhibition of Cancer Cells by Enzyme-Induced Gain of Function of Phosphorylated Melittin Analogues.

Mechanistic insights into Rho/MRTF inhibition-induced apoptotic events and prevention of drug resistance in melanoma: Implications for the involvement of pirin

Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma

Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells

Inhibition of the Rho/MRTF pathway improves the response of BRAF‐resistant melanoma to PD1/PDL1 blockade

A Polymer–lipid Membrane Artificial Cell Nanocarrier Containing Enzyme–oxygen Biotherapeutic Inhibits the Growth of B16F10 Melanoma in 3D Culture and in a Mouse Model

Design and Biological Evaluation of Novel Triaryl Pyrazoline Derivatives with Dioxane Moiety for Selective BRAFV600E Inhibition.

Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma

Biological Activity of α-MSH–Peptide Conjugates

AACR - NCI - EORTC international conference on molecular targets and cancer therapeutics: highlights

Peptide-modified Vemurafenib-Loaded Liposomes for Targeted Inhibition of Melanoma Via the Skin.

Strongly ROS-Correlated, Time-Dependent, and Selective Antiproliferative Effects of Synthesized Nano Vesicles on BRAF Mutant Melanoma Cells and Their Hyaluronic Acid-Based Hydrogel Formulation

Notizen zur Cytotaxonomie und Evolution der GattungArtemisia

Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells